Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 247

Similar articles for PubMed (Select 22836070)

1.

Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.

Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstøl K, Arnesen KE, Ose L.

J Clin Lipidol. 2012 Jul-Aug;6(4):331-9. doi: 10.1016/j.jacl.2012.03.004. Epub 2012 Mar 23.

PMID:
22836070
2.

Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.

Zwiener RJ, Uauy R, Petruska ML, Huet BA.

J Pediatr. 1995 May;126(5 Pt 1):728-35.

PMID:
7751996
3.

Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.

Goldammer A, Wiltschnig S, Heinz G, Jansen M, Stulnig T, Hörl WH, Derfler K.

Metabolism. 2002 Aug;51(8):976-80.

PMID:
12145769
4.

Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.

Vishwanath R, Hemphill LC.

J Clin Lipidol. 2014 Jan-Feb;8(1):18-28. doi: 10.1016/j.jacl.2013.11.002. Epub 2013 Nov 8.

PMID:
24528684
5.

Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.

Bambauer R, Olbricht CJ, Schoeppe E.

Ther Apher. 1997 Aug;1(3):242-8.

PMID:
10225746
6.

The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.

Yamamoto A, Harada-Shiba M, Endo M, Kusakabe N, Tanioka T, Kato H, Shoji T.

Atherosclerosis. 2006 May;186(1):126-31. Epub 2005 Jul 25.

PMID:
16043185
8.

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T.

Am J Cardiol. 1998 Dec 15;82(12):1489-95.

PMID:
9874053
9.

Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).

Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M, Fujii T, Sakuma I, Fukami K, Honda T, Ogawa H, Yamagishi M.

J Am Coll Cardiol. 2002 Jul 17;40(2):220-7.

PMID:
12106923
10.
11.

Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.

Nenseter MS, Narverud I, Græsdal A, Bogsrud MP, Aukrust P, Retterstøl K, Ose L, Halvorsen B, Holven KB.

J Clin Lipidol. 2013 Mar-Apr;7(2):109-16. doi: 10.1016/j.jacl.2012.08.001. Epub 2012 Aug 8.

PMID:
23415429
14.

Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years.

Palcoux JB, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger JL, Brignon P, Roussel B.

Ther Apher Dial. 2008 Jun;12(3):195-201. doi: 10.1111/j.1744-9987.2008.00574.x.

PMID:
18503695
15.

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia.

Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. Epub 2014 Jul 22.

16.

Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.

Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR.

J Lipid Res. 1997 Oct;38(10):2071-8.

17.

Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia.

Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ.

Arch Intern Med. 2003 Jan 13;163(1):65-8.

PMID:
12523918
18.

Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: a 4 year follow-up study.

Fadul JE, Vessby B, Wikström B, Danielson BG.

Artif Organs. 1997 May;21(5):364-8.

PMID:
9129767
19.

The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.

Vogt A, Parhofer KG.

Expert Opin Pharmacother. 2013 Apr;14(6):691-7. doi: 10.1517/14656566.2013.779253. Epub 2013 Mar 11.

PMID:
23477485
20.

Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia.

Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR.

Am J Cardiol. 2008 Nov 1;102(9):1199-204. doi: 10.1016/j.amjcard.2008.06.049. Epub 2008 Sep 5.

PMID:
18940291
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk